Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-20-001020
Filing Date
2020-04-16
Accepted
2020-04-16 21:51:42
Documents
1
Period of Report
2020-04-13

Document Format Files

Seq Description Document Type Size
1 form4-04162020_060431.html 4  
1 form4-04162020_060431.xml 4 4622
  Complete submission text file 0001415889-20-001020.txt   6073
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Issuer) CIK: 0001604191 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address
Oakes Gregory (Reporting) CIK: 0001809796 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37853 | Film No.: 20797577